文献速递慢性肾脏病遗传性与小管间质肾病

尿/血浆尿素比值可预测常染色体显性多囊肾病进展

Use of the Urine-to-Plasma Urea Ratio to Predict ADPKD Progression.
PubMed 文献 · Clin J Am Soc Nephrol · 2021-01-27

本研究在30例ADPKD患者中验证尿/血浆尿素比值(U/P尿素)与最大尿浓缩能力高度相关(R=0.90),并在583例ADPKD患者中评估其与肾脏预后的关联。中位随访4.0年,U/P尿素比值与eGFR下降速率独立相关(β=0.58,P=0.02),比值每降低10单位,快速进展性疾病风险增加(OR=1.35,95%CI 1.19-1.52,P<0.001)。U/P尿素比值联合Mayo Clinic影像分类和PKD基因突变可更好预测快速进展。

要点

  • U/P尿素比值与最大尿浓缩能力高度相关(R=0.90,P<0.001)。
  • U/P尿素比值每降低10单位,快速进展风险增加35%(OR=1.35,95%CI 1.19-1.52)。
  • U/P尿素比值联合Mayo影像分类和PKD突变预测效能优于单一指标。

核心结论

  • 尿/血浆尿素比值可预测ADPKD疾病进展,且独立于已有风险标志物。

研究设计与样本

  • 在30例ADPKD患者中验证U/P尿素比值与最大尿浓缩能力相关性;在583例ADPKD患者中评估其与肾脏结局关联,采用多变量混合模型回归和逻辑回归。

主要发现

  • U/P尿素比值与最大尿浓缩能力高度相关(R=0.90,P<0.001)。
  • 中位随访4.0年(IQR 2.6-5.0),U/P尿素比值与eGFR下降速率显著相关(β=0.58,P=0.02),校正已有预测因子后仍显著。
  • U/P尿素比值每降低10单位,快速进展性疾病(eGFR年下降≥3.0 ml/min/1.73m²)的OR为1.35(95%CI 1.19-1.52,P<0.001)。
  • U/P尿素比值、Mayo Clinic身高校正总肾脏体积分类和PKD基因突变联合风险评分预测快速进展优于各单一预测因子。

临床怎么用

  • U/P尿素比值基于常规实验室检查计算,可辅助识别早期ADPKD快速进展高风险患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Predicting disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD) poses a challenge, especially in early-stage disease when kidney function is not yet affected. Ongoing growth of cysts causes maximal urine-concentrating capacity to decrease from early on. We therefore hypothesized that the urine-to-plasma urea ratio, as a reflection of the urine-concentrating capacity, can be used as a marker to predict ADPKD progression. DESIGN: The urine-to-plasma urea ratio was calculated by dividing concentrations of early morning fasting spot urine urea by plasma urea. First, this ratio was validated as surrogate marker in 30 patients with ADPKD who underwent a prolonged water deprivation test. Thereafter, association with kidney outcome was evaluated in 583 patients with ADPKD with a broad range of kidney function. Multivariable mixed-model regression was used to assess association with eGFR slope, and logarithmic regression to identify patients with rapidly progressive disease, using a cutoff of -3.0 ml/min per 1.73 m2 per year. The urine-to-plasma urea ratio was compared with established predictors, namely, sex, age, baseline eGFR, Mayo Clinic height-adjusted total kidney volume class, and PKD gene mutation. RESULTS: The maximal urine-concentrating capacity and urine-to-plasma urea ratio correlated strongly (R=0.90; P<0.001). Next, the urine-to-plasma urea ratio was significantly associated with rate of eGFR decline during a median follow-up of 4.0 (interquartile range, 2.6-5.0) years, both crude and after correction for established predictors (β=0.58; P=0.02). The odds ratio of rapidly progressive disease was 1.35 (95% confidence interval, 1.19 to 1.52; P<0.001) for every 10 units decrease in urine-to-plasma urea ratio, with adjustment for predictors. A combined risk score of the urine-to-plasma urea ratio, Mayo Clinic height-adjusted total kidney volume class, and PKD mutation predicted rapidly progressive disease better than each of the predictors separately. CONCLUSIONS: The urine-to-plasma urea ratio, which is calculated from routine laboratory measurements, predicts disease progression in ADPKD in addition to other risk markers. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2021_01_27_CJN10470620_final.mp3.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Heida JE, Gansevoort RT, Messchendorp AL, et al. Use of the Urine-to-Plasma Urea Ratio to Predict ADPKD Progression. Clin J Am Soc Nephrol. 2021. PMID: 33504546. doi:10.2215/CJN.10470620

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。